OOIR: Observatory of International Research

Papers

(The TQCC of Leukemia Research is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Editorial Board	27
THE TITO BASTIANELLO AND MDSF YOUNG INVESTIGATORS AWARDS	24
GUIDED POSTER VIEWING SESSION 1: THERAPY - PART I	21
MDSF - EHA JOINT SESSION	21
Outcomes with high dose cytarabine and mitoxantrone induction for adults with mixed phenotype acute leukemia	20
Editorial Board	19
DONOR-DERIVED B-LYMPHOBLASTIC LYMPHOMA FOLLOWING RENAL TRANSPLANT: A CASE REPORT	18
SOX11 AND EPSTEIN–BARR VIRUS MAY SUBSTITUTE EACH OTHER IN EARLY PATHOGENESIS OF BURKITT LYMPHOMA	18
TARGETED THERAPY INCREASES PD-L1 PROTEIN EXPRESSION IN CELL LINES OF MEDIASTINAL LYMPHOMA	18
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: HIGHER LEPTIN LEVEL IS ASSOCIATED WITH MYELODYSPLASTIC SYNDROME: A COMPARATIVE STUDY	17
Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche: MESENCHYMAL STROMAL CELLS OF THE BONE MARROW NICHE CONTRIBUTE TO THE PROINFLAMMATORY PHENOTYPE OF CMML MONOCYTES TH	16
Topic: AS01-Diagnosis/AS01a-Cytomorphology: ARTIFICIAL INTELLIGENCE MAY HELP THE HEMATOPATHOLOGIST IN EVALUATION OF BONE MASS AND CELLULARITY IN BONE MARROW SPECIMENS OF PATIENTS WITH MDS	16
MDS AND AUTO-IMMUNITY	16
5-AZACYTIDINE IN COMBINATION WITH A NOVEL PAN-LYSYL OXIDASE INHIBITOR SYNERGISTICALLY RESTORES ERYTHROPOIESIS IN MYELODYSPLASTIC MALIGNANCIES	16
EFFICACY AND SAFETY OF SEQUENTIAL DIFFERENT B CELL ANTIGEN-TARGETED CAR T-CELL THERAPY FOR PEDIATRIC REFRACTORY/ RELAPSED BURKITT LYMPHOMA WITH SECONDARY CENTRAL NERVOUS SYSTEM INVOLVEMENT	16
Topic: AS04-MDS Biology and Pathogenesis/AS04a-Normal, MDS, and leukemic stem cells: DER(1;7)(Q10;P10) DEFINES A DISTINCT SUBTYPE OF MYELODYSPLASIA	16
CHARACTERIZATION OF TRANSCRIPTIONAL ALTERATIONS LEADING TO ABERRANT MYELOID DIFFERENTIATION IN MYELODYSPLASTIC SYNDROMES	15
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)	15
ALK INHIBITORS SAFETY PROFILE IN PEDIATRIC PATIENTS TREATED FOR AN ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA: REAL LIFE EXPERIENCE AMONG A FRENCH COHORT	14
DISTINCT PATHOGENESIS OF CLONAL HEMATOPOIESIS REVEALED BY SINGLE-CELL MULTI-OMICS SEQUENCING	14
Time to first treatment is an independent prognostic factor for Multiple Myeloma (MM)	14
Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia	13
Bortezomib-resistant multiple myeloma patient-derived xenograft is sensitive to anti-CD47 therapy	13
Comparison of a modified pediatric protocol versus a hyper-CVAD protocol in adolescents and young adults with Philadelphia-negative acute lymphoblastic leukemia: A multicenter retrospective analysis	12
Prognostic value of ASXL1 mutations in acute myeloid leukemia: A meta-analysis	12

Discovery of METTL3 inhibitor C191-0266 as a leukemia therapeutic through targeted modulation of protective autophagy	12
Changing frontline AML treatment patterns from 2013 to 2022	12
Editorial Board	12
Pathogenic mechanisms and targeted therapies for anemia in myelodysplastic syndromes	12
Acute leukemias with complex karyotype show a similarly poor outcome independent of mixed, myeloid or lymphoblastic immunophenotype: A study from the Bone Marrow Pathology Group	11
Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling	11
How low can you go?: Methodologic considerations in clonal hematopoiesis variant calling	11
Editorial Board	10
ASSEMBLING A RARE NON-HODGKIN LYMPHOMA COHORT: EARLY FINDINGS FROM “THE UMBRELLA STUDY”	10
PROGNOSIS - PROGNOSTIC FACTORS OF OUTCOME AND RISK ASSESSMENT	10
Risk factors and fluid management in tumor lysis syndrome of acute myeloid leukemia: A retrospective study	10
Allogeneic stem cell transplant with TBI-based myeloablative conditioning in adolescents and young adults with Philadelphia chromosome-negative ALL treated with pediatric protocols	10
GUIDED POSTER VIEWING SESSION 1: THERAPY - PART II	10
A phase I clinical trial of lenalidomide combined with bortezomib for acute myeloid leukemia or myelodysplastic syndrome relapsing after allogeneic stem cell transplantation	10
Comparison of adverse event profiles of carfilzomib-, elotuzumab-, and ixazomib-based therapies combined with lenalidomide and dexamethasone in patients with multiple myeloma using VigiBase	10
Editorial Board	10
Exploring the pathogenesis of extranodal natural killer/T cell lymphoma complicated With EBV via microarray data analysis	10
MDS BIOLOGY AND PATHOGENESIS - CLONAL DIVERSITY & EVOLUTION	9
A RARE CASE OF PRIMARY OCULAR POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER IN A BRAZILIAN CHILD	9
IMPACT OF RITUXIMAB ON IMMUNE STATUS FOLLOWING THERAPY IN CHILDREN AND ADOLESCENTS WITH HIGH-RISK MATURE B-CELL NON-HODGKIN LYMPHOMA: RESULTS OF THE INTER-B-NHL RITUX 2010 TRIAL	9
DIAGNOSIS - CYTOMORPHOLOGY AND HISTOLOGY	9
Hyperleukocytosis in patients with acute myeloid leukemia admitted to the intensive care unit: a single-center retrospective analysis	9
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: CMML PATIENTS WITH LOW EXPRESSION OF TP53 POINT TO AML TRANSFORMATION	9
The impact of different FLT3-inhibitors on overall survival of de novo acute myeloid leukemia: A network meta-analysis	9
GUIDED POSTER VIEWING SESSION 2: FUNDAMENTAL	9
Clinical strategies for leukemia management: Recommendations from the Bridging the Gaps in Hematology Oncology Consensus Conference 2025	9
MCL-1 INHIBITORS INDUCES APOPTOSIS IN VITRO IN BURKITT LYMPHOMA CELL LINES AND INHIBITS IN VIVO BURKITT LYMPHOMA PROGRESSION	9
Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation	8
Pregnancy and long-term outcomes of female patients with chronic myeloid leukemia on tyrosine kinase inhibitors who experienced unplanned pregnancies	8
IS TRANSCRIPTIONAL CELL STATE THE KEY TO PREDICTING RESISTANCE IN BURKITT LYMPHOMA?	8
MicroRNAS DOWNREGULATE TUMOR SUPPRESSOR GRK2 IN MALT1-DEPENDENT DIFFUSE LARGE B-CELL LYMPHOMA	8
FULMINANT, EBV DRIVEN PLASMACYTIC POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) WITH LOSS OF 1P AND GAIN OF TP53/CEP17 AND IGH BONE MARROW INVOLVEMENT AFTER LIVER TRANSPLANT IN 17-MONTH OLD BOY	8
FDG-PET/CT IMAGING IN PEDIATRIC PRECURSOR B-CELL LYMPHOBLASTIC LYMPHOMA (BCP-LBL) SHOWS BONE (MARROW) INVOLVEMENT IN A VAST MAJORITY OF PATIENTS	8
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: PHASE 1 STUDY EVALUATING LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) P	8
IL1B rs1143627 and IL17A rs8193036 in the risk of Acute Graft Versus Host Disease in pediatric HSCT	8
Identification of ZNF384 as a regulator of epigenome in leukemia	8
ACCELERATED RNA SPLICING DYNAMICS DURING ERYTHROID DIFFERENTIATION AMPLIFY MIS-SPLICING IN SF3B1-MUTANT MDS-RS	8
Topic: AS09-Quality of life-Disease experiences: ANEMIA OF CHRONIC DISEASE IN THE ELDERLY: EVALUATION OF HEPCIDIN EXPRESSION AND ITS RELATIONSHIP WITH PROINFLAMMATORY CYTOKINES AND CLINICAL AND LABORA	8
EXTRACELLULAR VESICLES AS KEY ORCHESTRATORS OF BONE MARROW NICHE REMODELING IN PEDIATRIC MATURE-B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	8
ALK+ ALCL EVADES IMMUNE SURVEILLANCE THROUGH NPM-ALK-DRIVEN EPIGENETIC REPRESSION OF Cd48	8
Roles of noncoding RNAs in multiple myeloma	8
Donor matters: Donor selection impact on hematopoietic stem cell transplantation outcomes in Hispanic patients with B-cell acute lymphocytic leukemia: Insights from a myeloablative HSCT study	8
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INCREASED DNA-CELL-CYCLE S-PHASE FRACTION IS RELATED TO INCREASED INCIDENCES OF IMMATURE MYELOID CELLS AND HIGH IPSS-R RI	8
PRE-TRANSPLANT TREATMENT OF HEPATISPLENIC T-CELL LYMPHOMA (GAMMA-DELATA): A PEDIATRIC CASE REPORT	8
CIRCULATING TUMOR DNA IN ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA: A PROOF-OF-CONCEPT STUDY	8
PARALLEL SESSION 01: TP53 IN MDS	7
Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/refractory FLT3 acute myeloid leukemia	7
Cutaneous manifestations of large granular lymphocytic leukemia: A case report and systematic review	7
RAPID FIRE SESSION 01	7
Canadian evidence-based guideline for treatment of relapsed/refractory chronic lymphocytic leukemia	7

Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: INTEGRATED ANALYSIS OF MDS-OMICS INFORMS ON DRUG RESPONSE PROFILES	7
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia	7
RAPID FIRE SESSION 02	7
Tyrosine kinase inhibitors combined with venetoclax and azacytidine as an effective therapy for de novo lymphoid blast phase-chronic myeloid leukemia	7
DIAGNOSIS - MOLECULAR ABERRATIONS (CYTOGENETIC, GENETIC, GENE EXPRESSION)	7
ADVANCES IN PEDIATRIC LYMPHOBLASTIC LYMPHOMA: DEMOGRAPHIC CLINICAL CHARACTERISTICS, TREATMENT AND LONG-TERM OUTCOME: INSTITUTIONAL EXPERIENCE OVER 30 YEARS	7
Topic: AS07-Singular Entities/Subtypes/AS07c-Hereditary MDS including predisposition syndromes: SECONDARY FINDINGS IN EXOME SEQUENCING IN 240 EARLY-ONSET ADULT MYELODYSPLASTIC SYNDROMES WITHOUT PREVIO	7
Editorial Board	7
MiR-409–3p regulates the proliferation and apoptosis of THP-1 through targeting Rab10	7
Cost-effectiveness of blinatumomab for the treatment of B‑precursor acute lymphoblastic leukemia pediatric patients with high‑risk first‑relapse in Mexico	7
Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy	7
RAPID FIRE SESSION 01	7
IMPROVING GLOBAL TREATMENT OUTCOMES OF CHILDREN DIAGNOSED WITH BURKITT LYMPHOMA	7
Topic: AS07-Singular Entities/Subtypes/AS07a-ARCH, CCUS, ICUS: PREVALENCE, DYNAMICS AND CLINICAL SIGNIFICANCE OF CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) IN NEWLY DIAGNOSED CANCER PATIEN	7
THE TCRB REPERTOIRE IN PEDIATRIC ALK-POSITIVE ALCL	7
Health system costs and autologous stem cell transplant receipt for participants with multiple myeloma in the Australian 45 and Up Study	7
Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience	6
18F-FDG-PET/CT IN THE ASSESSMENT OF BONE MARROW INVOLVEMENT IN PEDIATRIC NON-HODGKIN LYMPHOMA- A SINGLE CENTER EXPEREIENCE	6
Corrigendum to “Bortezomib-resistant multiple myeloma patient-derived xenograft is sensitive to anti-CD47 therapy” [Leuk. Res. 122 (2022) 106949]	6
THE CHALLENGE OF PROSPECTIVE DISTINCTION BETWEEN NON-NEOPLASTIC VERUS NEOPLASTIC EBV-ASSOCIATED HLH	6
Thiotepa-busulfan-fludarabine conditioning as a promising approach prior to haploidentical allogeneic hematopoietic stem cell transplantation in hematological malignancies with extramedullary involvem	6
Impact of the quantity and quality of the skeletal muscle on survival among patients undergoing allogeneic hematopoietic stem cell transplantation	6
VARIANT ALK-FUSION POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA (ALCL): A POPULATION-BASED COHORT OF THE NHL-BFM STUDY GROUP	6
PYRIMETHAMINE, A STAT3 INHIBITOR, HAS SYNERGY WITH VENETOCLAX AND IS EFFICACIOUS IN HYPOMETHYLATING AGENT RESISTANT MDS/AML	6
High JAK2V617F allele burden in low-risk PV: an additional recommendation to start “early” cytoreduction? Results from a multicentric study	6
Alternating venetoclax/azacytidine and FLT3 inhibitor treatment for NPM1- and FLT3-mutated acute myeloid leukemia	6
PRINCIPAL ACTIONS OF THE MYELODYSPLASTIC SYNDROME HSCT AMERICAN LATIN REGISTRY	6
BCL2 FAMILY INHIBITORS	6
CLINICAL, HISTOLOGICAL, AND GENETIC CHARACTERIZATION OF AGGRESSIVE B-CELL LYMPHOPROLIFERATIONS IN PATIENTS WITH INBORN ERRRORS OF IMMUNITY	6
GUIDED POSTER VIEWING SESSION 1: THERAPY - PART I	6
LncRNA MEG3 promotes the sensitivity of bortezomib by inhibiting autophagy in multiple myeloma	6
Topic: AS01-Diagnosis/AS01a-Cytomorphology: DIAGNOSTIC CHALLENGE BETWEEN WHO AND ICC CLASSIFICATION	6
Topic: AS01-Diagnosis/AS01b-Flow cytometry: IMMUNOPHENOTYPIC BONE MARROW CHARACTERISTICS IN MYELODYPLASTIC SYNDROME WITH SF3B1 MUTATION	6
PARALLEL SESSION 05: PREDICTIVE MODELS FOR RESPONSE IN HIGH RISK MDS	6
PLENARY SESSION 05: MDS CLASSIFICATION IN 2025	6
PEDIATRIC LOW GRADE LYMPHOMAS: A REPORT FROM A SINGLE CENTRE	6
BONE MARROW INFILTRATION AS A PROGNOSTICE FACTOR IN PEDIATARIC BURKITT LYMPHOMA PATIENTS	6
Assessing the associations of blood metabolites with myelodysplastic syndrome: A bidirectional mendelian randomization study	6
TREATMENT - CURRENT TREATMENT OPTIONS - HIGHER RISK MDS	6
Advances in diagnosis, treatment and prognostic factors of gastrointestinal DLBCL	6
CURRENT CARDIOVASCULAR DISEASE (CVD) RISK PREDICTION MODELS ARE NOT APPLICABLE IN MDS PATIENTS: PRELIMINARY RESULTS OF A PROSPECTIVE OBSERVATIONAL SINGLE-CENTRE COHORT STUDY	6
TREATMENT - NEW DEVELOPMENTS - PRECLINICAL STUDIES	6
PARALLEL SESSION 04: PREDICTIVE MODELS FOR RESPONSE IN LOW RISK MDS	6
Identification and characterization of peptidyl-prolyl isomerase Pin1 as a new regulatory component of BCR::ABL1 degradation	5
PROGNOSIS - PREDICTIVE FACTORS OF RESPONSE TO TREATMENT	5
NPM::ALK TRANSCRIPT LEVELS AND ANTI-ALK AUTOANTIBODY TITERS AS BIOMARKERS FOR OUTCOME IN PEDIATRIC ALK+ ANAPLASTIC LARGE CELL LYMPHOMA TREATED WITH BRENTUXIMAB VEDOTIN OR CRIZOTINIB IN COMBINATION WIT	5
PEDIATRIC NON-HODGKIN LYMPHOMA IN THE TURKISH PEDIATRIC CANCER REGISTRY (2009–2024) (TPOG & TPHD DATA)	5
Topic: AS08-Treatment/AS08a-Current treatment options – Higher risk MDS: VENETOCLAX AND AZACYTIDINE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES, A REAL-WORLD EXPERIENCE. LATIN-AMERICAN MDS GROUP – GLAM	5
Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study	5
Systematic review and meta-analysis evaluating clinical outcomes in adult acute myeloid leukemia patients with central nervous system involvement	5
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: LUSPATERCEPT IN LOWER-RISK MDS TRANSFUSION-DEPENDENT PATIENTS; A SINGLE-CENTRE EXPERIENCE	5
Universal posttransplant cyclophosphamide after allogeneic transplant, a retrospective single institution study	5
Distinct mutational and clinicopathologic profiles characterize acute myeloid leukemia with cup-like nuclei	5
QOL	5
SPECIFIC DISEASE ENTITIES - HEREDITARY MDS INCLUDING PREDISPOSITION SYNDROMES	5
RARE CASE OF COMPOSITE LYMPHOMA IN ADOLESCENT PATIENT – DIAGNOSTIC AND TREATMENT CHALLENGES	5
ANALYSIS OF THE CLINICAL CHARACTERISTICS AND PROGNOSTIC FACTORS OF MULTICENTER CHILDHOOD BURKITT LEUKEMIA	5
A critical evaluation of the EFS endpoint in AML: Does induction treatment failure timing have a profound impact on study design and results?	5
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: LUSPATERCEPT FOR PATIENTS WITH LOWER RISK MDS ADMITTED TO THE HEMATOLOGY DEPARTMENT OF THE COLENTINA CLINICAL HOSPITAL - DATA FR	5
PI3K/AKT inhibitor BEZ-235 targets CCND2 and induces G1 arrest in breast implant-associated anaplastic large cell lymphoma	5
Outcome of adolescents and young adult acute myeloid leukemia patients compared with middle-aged patients: A single centre retrospective experience	5
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: MUTATION-SPECIFIC HSPC ENRICHMENT PATTERNS UNDERLIE PROGNOSTICALLY SIGNIFICANT TRANSCRIPTOMIC SUBGROUPS OF MDS PATIENTS	5
Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: SELECT-MDS-1 TRIAL IN PROGRESS: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF TAMIBAROTENE/AZACITIDINE VS PLACEBO/AZACITID	5
Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation – Post-transplantation treatment: IN VIVO DUAL T CELL DEPLETION (TCD) IMPROVES TRANSPLANT OUTCOMES IN MYELODYSPLASTIC SYNDROME	5
NAP1L5 promotes epithelial–mesenchymal transition by regulating PEG10 expression in acute myeloid leukaemia	5
Diagnostic updates and research advances in AML-MR: Integrating molecular genetics and immune mechanisms	5
GERMLINE VARIANTS OF PIK3CD AND PIK3R1 IN PEDIATRIC NON-HODGKIN LYMPHOMA: INSIGHTS INTO THE ROLE OF APDS-ASSOCIATED ALTERATIONS	5
ENHANCING CD20.CAR NK CELL THERAPY IN RITUXIMAB-RESISTANT BURKITT LYMPHOMA USING IL-15-BASED IMMUNOMODULATORS WITH NKTR-255 OR ANTI-CD16-IL15-ANTI-CD19 TRIKE	5
SEARCHING FOR THE CAUSES OF ANAPLASTIC LARGE CELL LYMPHOMA	5
Impact of FLT3 inhibitors on the outcomes of FLT3-ITD mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant: A systematic review and meta-analysis	5
Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study	5
IMMUNOGLOBULIN SUBCLASSES OF ANTI-ALK ANTIBODIES IN PEDIATRIC ANAPLASTIC LARGE CELL LYMPHOMA	5
A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia	4
PEDIATRIC AND YOUNG ADULT ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA GENETICALLY DIFFERS FROM THE ADULT COUNTERPART	4
CLINICAL OUTCOME PREDICTION IN PEDIATRIC PRIMARY MEDIASTINAL B CELL LYMPHOMA – A JOINT BFM AND INTER-B-NHL RITUX 2010 ANALYSIS	4
Unmutated IGHV at diagnosis in patients with early stage CLL independently predicts for shorter follow-up time to first treatment (TTFT)	4
Topic: AS07-Singular Entities/Subtypes/AS07c-Hereditary MDS including predisposition syndromes: BEYOND DDX41: DDH AND DHX HELICASES ARE MUTATED IN MDS	4
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: THE EVOLVING GENETIC LANDSCAPE OF PEDIATRIC MDS-EB	4
Editorial Board	4
MDS BIOLOGY AND PATHOGENESIS - IMMUNE DEREGULATION / INFLAMMATION	4

Therapeutic advances for the management of adult T cell leukemia: Where do we stand?	4
Recent progress in pathological understanding of adult T-cell leukemia/lymphoma in the new classification era	4
GUIDED POSTER VIEWING SESSION 1: THERAPY - PART II	4
RITUXIMAB CLEARANCE IN PEDIATRIC PATIENTS WITH MAATURE B-CELL NON-HODGKIN LYMPHOMA	4
VARYING OUTCOMES OF MATURE T AND NK LYMPHOMA IN PEDIATRIC AND ADOLESCENT/YOUNG ADULT PATIENTS: A SINGLE INSTITUTION EXPERIENCE	4
CLINICAL CHARACTERISTICS AND TREATMENT EVALUATION OF DIFFUSE LARGE B-CELL LYMPHOMA IN CHINESE CHILDREN AND ADOLESCENTS: A MULTICENTER CLINICAL STUDY OF CHINA-NET CHILDHOOD LYMPHOMA GROUP B-NHL-2017	4
Outcomes of patients with acute myeloid leukemia treated with intensive therapy after failure of venetoclax-inclusive, less-intensive therapy	4
CHARACTERIZING THROMBOSIS IN CHILDREN & ADOLESCENTS WITH PRIMARY MEDIASTINAL B-CELL LYMPHOMA	4
Editorial Board	4
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: LONG-TERM MUTATIONAL DYNAMICS IN DEL(5Q) MDS PATIENTS EARLY TREATED WTIH LENALIDOMIDE (SINTRAREV CLINICAL TRIAL). SAFE	4
Pre-transplant blinatumomab and/or inotuzumab ozogamicin therapy for relapsed/refractory acute lymphoblastic and B/myeloid mixed phenotype acute leukemia in adults	4
Real-world treatment patterns and clinical outcomes of patients with treatment-naïve and relapsed/refractory diffuse large B-cell lymphoma in the United States	4
Editorial Board	4
ALK INIHIBITOR THERAPY IN ALCL	4
Alternative polyadenylation quantitative trait loci contribute to acute myeloid leukemia risk genes regulation	4
SPECIFIC DISEASE ENTITIES - MDS WITH RING SIDEROBLASTS/SF3B1	4
Association between myeloid disorders and adult onset-inflammatory syndromes, successful treatment with JAK-inhibitors: Case series and literature review	4
TARGETING PRIMARY CENTRAL NERVOUS SYSTEM B CELL LYMPHOMA IgH CLONOTYPES USING NOVEL RNA-NPs	4
Topic: AS01-Diagnosis/AS01b-Flow cytometry: COMMITTED AND IMMATURE ERYTHROID PROGENITORS ARE DIFFERENTLY DISTRIBUTED IN LOWER RISK MYELODYSPLASTIC SYNDROMES ACCORDING TO WHO CATEGORY AND CORRELATE WIT	4
MDS BIOLOGY AND PATHOGENESIS - CLONAL DIVERSITY & EVOLUTION	4
PDGFRβ DRIVES PROGRESSION BY ONCOGENE TRANSCRIPTION THROUGH STAT3/STAT5 HYPERACTIVATION IN ALCL	4
CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123	4
Immunological aspects of HTLV-1 persistence; for the prevention and treatment of Adult T-cell leukaemia-lymphoma (ATL)	4
RAPID FIRE SESSION 01	4
Editorial Board	3
Topic: AS01-Diagnosis/AS01a-Cytomorphology: NON-INVASIVE WEB-BASED DIAGNOSTIC ALGORITHM FOR MDS – MODEL PERFORMANCE AND VALIDATION	3
EPSTEIN-BARR VIRUS ORCHESTRATE THE TUMOR MICROENVIRONMENT OF BURKITT LYMPHOMA	3
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: ROUTINE INFLAMMATORY MARKERS ARE ELEVATED IN MYELODYSPLASTIC SYNDROMES AT PRESENTATION	3
The effect of body mass index on the safety of bosutinib in patients with chronic leukemia: A post hoc pooled data analysis	3
Effect of single-unit transfusion in patients treated for haematological disease including acute leukemia: A multicenter randomized controlled clinical trial	3
Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine	3
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): MUTATIONS OF SF3B1 GENE AND ITS SIGNIFICANCE ON PATIENTS WITH MYELODYSPASTIC SYNDROMES (MDS)	3
Optimal therapeutic strategies in relapsed/refractory AML with prior exposure to venetoclax-based therapy	3
COMBINATIONAL NATAURAL KILLER (NK) CELL-BASED IMMUNOTHERAPY TO CIRCUMVENT RESISTANCE IN RITUXIMAB-RESISTANT BURKITT LYMPHOMA (BL)	3
Assessing the value of measuring frailty in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma	3
Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: RESISTANCE TO HYPOMETHYLATING AGENTS (HMA) IN HIGH-RISK MYELODYSPLASTIC SYNDROME (HR-MDS): THE ROLE OF THE ADENOSINE DEAMINASE	3
BCR EXPRESSION IN BURKITT LYMPHOMA: NEW INSIGHT IN MUTATIONAL LANDSCAPE	3
Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy	3
Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort	3
Topic: AS01-Diagnosis/AS01a-Cytomorphology: AUTOMATED DIGITAL TOOL FOR MDS AND MDS/MPN CLASSIFICATION USING WHO AND ICC: INTERNATIONAL GUIDELINES WORKING GROUP ON MDS DIAGNOSIS, PROGNOSIS, AND GERMLIN	3
AN UNUSUAL PRESENTATION OF A RARE PEDIATRIC DISEASE	3
CONSTRUCTION AND CHARACTERIZATION OF A SINGLE-CENTER NON-HODGKIN LYMPHOMA PDX MODEL LIBRARY	3
MOLECULAR GENETICS ANALYSIS OF B-CELL PRECURSOR LYMPHOMA IN PEDIATRIC AND ADOLESCENT PATIENTS REVEALS HIGH FREQUENCY OF KMT2A TRANSLOCATIONS	3
Editorial Board	3
Single cell transcriptomics derived combinatorial markers distinguished leukemic stem cells from hematopoietic stem cells in acute myeloid leukemia	3
GUIDED POSTER VIEWING SESSION 1: THERAPY - PART II	3
GLOFITAMIB PLUS R-ICE (RITUXIMAB, IFOSFAMIDE, CARBOPLATIN, ETOPOSIDE) OR AS MONOTHERAPY IN CHILDREN AND ADOLESCENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (B-NHL): ANALYSIS FROM THE iMAT	3
COVID-19 infection in adult and paediatric recipients of allogeneic stem cell transplantation: The UK experience	3
Serum hypoalbuminemia is an independent prognostic factor in Chronic Myelomonocytic Leukemia (CMML),	3
Clonal hematopoiesis and age-associated degenerative disorders	3
A comprehensive comparison between TBI vs non-TBI-based conditioning regimen in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis	3
Validation of Molecular International Prognostic Scoring System (IPSS-M) in myelodysplastic/myeloproliferative neoplasms, not otherwise specified (MDS/MPN-NOS)	3
CLINICAL SPECTRUM OF PRECURSOR B-CELL LYMPHOBLASTIC MALIGNANCIES: A LARGE COHORT STUDY OF 364 PEDIATRIC PATIENTS	3
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: LUSPATERCEPT IN THE TREATMENT OF MDS PATIENTS. A SINGLE CENTER EXPERIENCE	3
Topic: AS04-MDS Biology and Pathogenesis/AS04c-MDS Mouse models (GEMMS, PDX): MAMMALIAN DIAPHANOUS-RELATED FORMIN 1 IS REQUIRED FOR MAINTAINING HEMATOPOIETIC STEM CELL QUIESCENCE AND SURVIVAL VIA REGU	3
PEDIATRIC INFRADIAPHRAGMATIC HODGKIN’S LYMPHOMA: A UNIQUE IDENTITY	3
Intensity of induction regimen and outcomes among adults with Ph+ALL undergoing allogeneic hematopoietic stem cell transplantation	3
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: SINGLE-CENTER EXPERIENCE WITH LUSPATERCEPT THERAPY IN LOW-RISK MYELODYSPLASTIC SYNDROME (LR-MDS) PATIENTS WITH TRANSFUSION DEPEN	3
Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemia	3
PROGNOSIS - PROGNOSTIC FACTORS OF OUTCOME AND RISK ASSESSMENT	3
SYSTEMIC EPSTEIN-BARR VIRUS-POSITIVE T-CELL LYMPHOMA OF CHILDHOOD: A CASE SERIES AND REVIEW OF THE LITERATURE	3
Growth and dormancy control of myeloma cells by mesenchymal stem cells	3
Safety, tolerability, and pharmacokinetics of ASP1235 in relapsed or refractory acute myeloid leukemia: A phase 1 study	3
Characteristics and survival outcomes of patients with myelodysplastic syndromes with isolated 11q deletion	3
Maternal obesity and acute lymphoblastic leukemia risk in offspring: A summary of trends, epidemiological evidence, and possible biological mechanisms	3
TP53 STATUS RISK STRATIFIES PATIENTS WITH CLINICALLY DEFINED HIGH-RISK DISEASE PAEDIATRIC B-CELL NON-HODGKIN LYMPHOMA	2
The relationship between clinical prognostic factors, microvascular density, and tumor-infiltrating lymphocytes with CD47 and SIRPα expression in diffuse large B cell lymphomas	2
Effect of cumulative daunorubicin dose on cardiotoxicity after allogeneic stem cell transplantation	2
THE TITO BASTIANELLO AND MDSF YOUNG INVESTIGATORS AWARDS	2
Clinical and immune features associated with chromosome 13q deletion and PRKCSH downregulation in newly diagnosed multiple myeloma	2
PRMT5 inhibitors for lower-risk myelodysplasia: Is there anywhere to move?	2
PLENARY SESSION 1: MOLECULAR PATHOGENESIS OF MDS	2
DIAGNOSIS - FLOW CYTOMETRY	2
Editorial Board	2
Determinants of clinical trial participation in multiple myeloma: A population-based cohort study from British Columbia	2
Predictive modeling of outcomes in acute leukemia patients undergoing allogeneic hematopoietic stem cell transplantation using machine learning techniques	2
Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines	2
Exploring the significance of MDM2 gene promoter variants in chronic myeloid leukemia	2
LINEAGE TRACING REVEALS CLONAL SELECTION DUE TO RITUXIMAB EXPOSURE IN BURKITT LYMPHOMA	2
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPROVED PROGNOSIS OF PATIENTS WITH MDS OVER FOUR DECADES: ANALYSIS FROM THE GERMAN MDS REGISTRY	2
ADOLESCENT AGE AT DIAGNOSIS MAY NEGATIVELY IMPACT CLINICAL OUTCOMES IN PEDIATRIC POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER	2
PLENARY SESSION 04: INTEGRATED MDS DIAGNOSTICS IN 2025	2
GUIDED POSTER VIEWING SESSION 2: FUNDAMENTAL	2
Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter study	2
Outside Front Cover - Journal name, Cover image, Volume issue details, ISSN, Cover Date, Elsevier Logo and Society Logo if required	2
Real-world analysis of the safety/tolerability of gilteritinib in combination with mold-active azole prophylaxis	2
Topic: AS07-Singular Entities/Subtypes/AS07c-Hereditary MDS including predisposition syndromes: GERMLINE PREDISPOSITION TO MYELOID MALIGNANCIES IN A CONSECUTIVE COHORT OF 183 PATIENTS	2
Emergence and continuous clonal evolution of a JAK2 exon 12-mutated myeloid clone after treatment for de novo acute myeloid leukemia	2
Author Index	2
Clinical characteristics, treatment pathway and resource utilisation for patients with chronic lymphocytic leukaemia: A multicentre retrospective study	2
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: CLINICAL AND MOLECULAR CHARACTERIZATION OF PATIENTS WITH THERAPY RELATED MYELOID NEOPLASMS	2
TREATMENT - CURRENT TREATMENT OPTIONS - HIGHER RISK MDS	2
GERMLINE DDX41 MUTATIONS : CLINICAL IMPACT & ETHNIC DIVERSITY	2
Title: Obesogenic microbial signatures and the development of obesity in childhood acute lymphoblastic leukemia	2
CRS and ICANS as class-level adverse event for CD20 ×CD3 bispecific T-cell engagers: A Bayesian analysis of a nationwide database	2